Apr. 16 at 12:40 AM
The attachment compares
$ZVRA valuation, analyst consensus & related multiples to the same from 11 peer commercial-stage biopharma M&A transactions.
Analysts forecast ZVRA to generate
$1.438B in revenues over the next 5 years (FY26 - 30). This is, more or less, consistent with the 5 year revenue forecasts prepared by the mgmt/BOD of
$SCPH BDSI & RDUS when they were acquired for enterprise values of
$300 to
$840MM.
ZVRA has
$176MM net cash/debt at 12/31/25 so their enterprise value is ~
$430MM (versus the
$606MM noted as market cap used to calculate multiples).
We're curious which, if any, peer of the 11 on the attachment that exited via M&A is a good comp for ZVRA.
Other bios with similar forecasts include
$CRMD $HRTX &
$AQST
We're only sharing our analysis. This is not investment advice.
